HC Wainwright set a $11.00 price target on Amyris (NASDAQ:AMRS) in a report released on Tuesday. The firm currently has a buy rating on the biotechnology company’s stock.

Several other research analysts have also recently weighed in on AMRS. Zacks Investment Research cut shares of Amyris from a hold rating to a sell rating in a research report on Tuesday, October 9th. BidaskClub cut shares of Amyris from a buy rating to a hold rating in a research report on Saturday, October 13th. Finally, B. Riley reduced their price target on shares of Amyris from $10.00 to $8.00 and set a buy rating on the stock in a research report on Wednesday, November 14th. One analyst has rated the stock with a sell rating, one has given a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of Buy and an average price target of $8.83.

AMRS stock opened at $5.70 on Tuesday. Amyris has a 1-year low of $2.64 and a 1-year high of $9.28.

Amyris (NASDAQ:AMRS) last posted its quarterly earnings data on Tuesday, November 13th. The biotechnology company reported ($1.13) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.96). The company had revenue of $14.90 million for the quarter, compared to the consensus estimate of $46.72 million. The company’s revenue was down 38.4% compared to the same quarter last year. During the same quarter last year, the business posted ($0.81) EPS. On average, analysts expect that Amyris will post -1.34 EPS for the current year.

In other Amyris news, CFO Kathleen Valiasek purchased 23,000 shares of Amyris stock in a transaction on Tuesday, November 27th. The shares were acquired at an average cost of $4.37 per share, for a total transaction of $100,510.00. Following the completion of the transaction, the chief financial officer now directly owns 251,630 shares of the company’s stock, valued at $1,099,623.10. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, COO Eduardo Alvarez purchased 11,834 shares of Amyris stock in a transaction on Thursday, December 13th. The shares were acquired at an average price of $4.23 per share, for a total transaction of $50,057.82. Following the completion of the transaction, the chief operating officer now directly owns 333,876 shares of the company’s stock, valued at $1,412,295.48. The disclosure for this purchase can be found here. 21.80% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently modified their holdings of the business. Wells Fargo & Company MN grew its position in Amyris by 50.6% during the third quarter. Wells Fargo & Company MN now owns 41,903 shares of the biotechnology company’s stock valued at $333,000 after acquiring an additional 14,075 shares during the last quarter. Schwab Charles Investment Management Inc. bought a new position in shares of Amyris in the second quarter worth approximately $292,000. Caption Management LLC bought a new position in shares of Amyris in the fourth quarter worth approximately $50,000. Gilder Gagnon Howe & Co. LLC bought a new position in shares of Amyris in the third quarter worth approximately $7,828,000. Finally, JPMorgan Chase & Co. grew its holdings in shares of Amyris by 96.2% in the third quarter. JPMorgan Chase & Co. now owns 446,909 shares of the biotechnology company’s stock worth $3,548,000 after purchasing an additional 219,081 shares during the last quarter. Institutional investors and hedge funds own 30.58% of the company’s stock.

About Amyris

Amyris, Inc, an integrated renewable products company, engages in the research, development, and production of ingredients for the health and wellness, clean beauty, and flavors and fragrances markets worldwide. It applies its bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products.

Further Reading: How to find the components of the quick ratio

Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.